The murine model for hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment

Journal of Virology

Volumn 87, Issue 20, 2013, Pages 10997-11007

  Chung, Dong Hoon ^a,b   Västermark, Åke ^c   Camp, Jeremy V ^a   McAllister, Ryan ^a   Remold, Susanna K ^b   Chu, Yong Kyu ^b   Bruder, Carl ^b   Jonssona, Colleen B ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC RNA; RIBAVIRIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; GENETIC SELECTION; GENETIC VARIABILITY; HANTAVIRUS; HANTAVIRUS INFECTION; HOST; LETHALITY; MOLECULAR EVOLUTION; MOUSE; MURINE MODEL; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SUCKLING; VIRUS GENOME; VIRUS INFECTIVITY;

ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; EVOLUTION, MOLECULAR; FEMALE; HANTAAN VIRUS; HEMORRHAGIC FEVER WITH RENAL SYNDROME; LUNG; MICE; MICE, INBRED ICR; MUTATION RATE; PREGNANCY; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84886929222     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01394-13     Document Type: Article

References (64)

1. Jonsson CB, Figueiredo LT, Vapalahti O. 2010. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23: 412-441.
2. Schmaljohn CS, Hooper JW. 2001. Bunyaviridae: the viruses and their replication, p 1581-1633. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Schmaljohn CS, Hasty SE, Harrison SA, Dalrymple JM. 1983. Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J. Infect. Dis. 148:1005-1012.
4. Peters CJ, Simpson GL, Levy H. 1999. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu. Rev. Med. 50:531-545.
5. Botten J, Mirowsky K, Ye C, Gottlieb K, Saavedra M, Ponce L, Hjelle B. 2002. Shedding and intracage transmission of Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus) model. J. Virol. 76:7587-7594.
6. Ebihara H, Yoshimatsu K, Ogino M, Araki K, Ami Y, Kariwa H, Takashima I, Li D, Arikawa J. 2000. Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence. J. Virol. 74:9245-9255.
7. Hutchinson KL, Rollin PE, Peters CJ. 1998. Pathogenesis of a North American hantavirus, Black Creek Canal virus, in experimentally infected Sigmodon hispidus. Am. J. Trop. Med. Hyg. 59:58-65.
8. Lokugamage K, Kariwa H, Lokugamage N, Iwasa M, Hagiya T, Araki K, Tachi A, Mizutani T, Yoshimatsu K, Arikawa J, Iwasaki T, Takashima I. 2004. Comparison of virulence of various hantaviruses related to hemorrhagic fever with renal syndrome in newborn mouse model. Jpn. J. Vet. Res. 51:143-149.
9. Hooper JW, Custer DM, Smith J, Wahl-Jensen V. 2006. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347:208-216.
10. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. 2001. A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6-14.
11. Huggins JW, Hsiang CM, CosgriffTM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Oland DD, Gui XE, Gibbs PH, Yuan GH, Zhang TM. 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1119-1127.
12. Huggins JW, Kim GR, Brand OM, McKee KT, Jr. 1986. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153: 489-497.
13. Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, Boudreau EF, CosgriffT, Pittman P, Kim KY, Erlichman MS, Rezvani DF, Huggins JW. 2009. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 81:68-76.
14. Safronetz D, Ebihara H, Feldmann H, Hooper JW. 2012. The Syrian hamster model of hantavirus pulmonary syndrome. Antiviral Res. 95: 282-292.
15. Bull JJ, Sanjuan R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. J. Virol. 81:2930-2939.
16. Daifuku R. 2003. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. BioDrugs 17:169-177.
17. Freistadt MS, Meades GD, Cameron CE. 2004. Lethal mutagens: broadspectrum antivirals with limited potential for development of resistance? Drug Resist. Updat. 7:19-24.
18. Jonsson CB, Milligan BG, Arterburn JB. 2005. Potential importance of error catastrophe to the development of antiviral strategies for hantaviruses. Virus Res. 107:195-205.
19. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16:37-48.
20. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947.
21. Malinoski F, Stollar V. 1981. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110:281-289.
22. Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89:830-836.
23. Toltzis P, Huang AS. 1986. Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells. Antimicrob. Agents Chemother. 29:1010-1016.
24. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:946-951.
25. Fernandez-Larsson R, O'Connell K, Koumans E, Patterson JL. 1989. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob. Agents Chemother. 33:1668-1673.
26. Wray SK, Gilbert BE, Knight V. 1985. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5:39-48.
27. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. (Berl.) 80:86-95.
28. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895-6900.
29. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83:5760-5764.
30. Vignuzzi M, Stone JK, Andino R. 2005. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107:173-181.
31. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. 1999. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J. Hepatol. 30:376-382.
32. +) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology 137:259-270.
33. Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB. 2007. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'- triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 51:84-88.
34. Chung DH, Sun Y, Parker WB, Arterburn JB, Bartolucci A, Jonsson CB. 2007. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J. Virol. 81:11722-11729.
35. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. 2003. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77: 481-488.
36. Takenaka A, Gibbs CJ, Jr, Gajdusek DC. 1985. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch. Virol. 84:197-206.
37. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
38. Schmaljohn CS, Jennings GB, Hay J, Dalrymple JM. 1986. Coding strategy of the S genome segment of Hantaan virus. Virology 155:633-643.
39. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL. 2010. Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 26:2455-2457.
40. Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, Parker WB, Smith J, Spik K, Ramanathan HN, Schmaljohn CS, Jonsson CB. 2008. Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res. 79:19-27.
41. Pond SL, Frost SD. 2005. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21:2531-2533.
42. Kosakovsky Pond SL, Frost SD. 2005. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 22:1208-1222.
43. Murrell B, Wertheim JO, Moola S, Weighill T, Scheffler K, Kosakovsky Pond SL. 2012. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 8:e1002764. doi:10.1371/journal.pgen.1002764.
44. Schmaljohn C, Hjelle B. 1997. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3:95-104.
45. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, Koster FT, Baum KF, Rollin PE, Pavia AT, Holman RC, Christenson JC, Rubin PJ, Behrman RE, Bell LJ, Simpson GL, Sadek RF. 1999. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 4:211-219.
46. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, Levy H, Koster FT, Baum K, Lindemulder A, Wang W, Riser L, Fernandez H, Whitley RJ. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39:1307-1313.
47. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. 2011. In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS One 6:e23560. doi:10.1371/journal.pone.0023560.
48. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58:183-205.
49. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
50. Graci JD, Cameron CE. 2002. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298:175-180.
51. Tam RC, Lau JY, Hong Z. 2001. Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 12:261-272.
52. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348.
53. Sanz-Ramos M, Rodriguez-Calvo T, Sevilla N. 2012. Mutagenesis-mediated decrease of pathogenicity as a feature of the mutant spectrum of a viral population. PLoS One 7:e39941. doi:10.1371/journal.pone.0039941.
54. Graci JD, Gnadig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE. 2012. Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J. Virol. 86:2869-2873.
55. Taylor SL, Krempel RL, Schmaljohn CS. 2009. Inhibition of TNF-alphainduced activation of NF-kappaB by hantavirus nucleocapsid proteins. Ann. N. Y. Acad. Sci. 1171(Suppl 1):E86-E93.
56. Ontiveros SJ, Li Q, Jonsson CB. 2010. Modulation of apoptosis and immune signaling pathways by the Hantaan virus nucleocapsid protein. Virology 401:165-178.
57. Li XD, Makela TP, Guo D, Soliymani R, Koistinen V, Vapalahti O, Vaheri A, Lankinen H. 2002. Hantavirus nucleocapsid protein interacts with the Fas-mediated apoptosis enhancer Daxx. J. Gen. Virol. 83:759-766.
58. Kaukinen P, Vaheri A, Plyusnin A. 2003. Non-covalent interaction between nucleocapsid protein of Tula hantavirus and small ubiquitinrelated modifier-1, SUMO-1. Virus Res. 92:37-45.
59. Tamura K, Nei M. 1993. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol. Biol. Evol. 10:512-526.
60. Jenison S, Yamada T, Morris C, Anderson B, Torrez-Martinez N, Keller N, Hjelle B. 1994. Characterization of human antibody responses to Four Corners hantavirus infections among patients with hantavirus pulmonary syndrome. J. Virol. 68:3000-3006.
61. Lee BH, Yoshimatsu K, Maeda A, Ochiai K, Morimatsu M, Araki K, Ogino M, Morikawa S, Arikawa J. 2003. Association of the nucleocapsid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. Virus Res. 98:83-91.
62. Plyusnin A, Vapalahti O, Lankinen H, Lehvaslaiho H, Apekina N, Myasnikov Y, Kallio-Kokko H, Henttonen H, Lundkvist A, Brummer-Korvenkontio M. 1994. Tula virus: a newly detected hantavirus carried by European common voles. J. Virol. 68:7833-7839.
63. Severson W, Xu X, Kuhn M, Senutovitch N, Thokala M, Ferron F, Longhi S, Canard B, Jonsson CB. 2005. Essential amino acids of the Hantaan virus N protein in its interaction with RNA. J. Virol. 79:10032-10039.
64. +) CTL epitopes on nucleocapsid protein. J. Virol. 73:5301-5308.